Clinical trials: Neural Degeneration
TBI-Traumatic Brain Injury
Simvastatin for mTBI
Study of simvastatin in Iraq/Afghanistan Veterans with multiple blast exposure and mTBI. The study will measure substances in cerebrospinal fluid (CSF) that are related to dementing disorders.
- Trial name
- NCT01952288
- Testing
- simvastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
This study will evaluate how improved cerebral blood flow affects the way in which newly formed MS lesions evolve and whether tissue repair is improved.
- Trial name
- perfuseMS (NCT02466074)
- Testing
- Acetazolamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Health Science Center, Houston
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Pantothenate Kinase-Associated Neurodegeneration
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN.
- Trial name
- NCT01741532
- Testing
- Deferiprone oral solution
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 89 people
- Sponsor
- ApoPharma
Parkinson's Disease
Early Parkinson's Disease Monotherapy With CVN424
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD).
- Trial name
- NCT06006247
- Testing
- CVN424 150 mg
- Where
- 42 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cerevance Beta, Inc.